Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like Low vitamin D tied to belly fat and weak muscles in women April 25, 2024 CAR-T cell therapy remains viable for patients in lymphoma remission, study finds December 11, 2023 Study reveals avocado may lower diabetes risk in women, not men April 23, 2024